PP-095 Analysis of the efficacy of treatment with peginterferon-α-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus  by Yu, J.-W. & Sun, L.-J.
Poster Presentations S53
PP-091 Telbivudine results in undetectable viremia
and improved liver function in a patient with
HBsAg-positive decompensated cirrhosis:
a case report
V. Messina1 *. 1UOC Malattie Infettive, AORN S. Anna e
S. Sebastiano di Caserta, Italy
Introduction: We report here the safety and efﬁcacy of
telbivudine in a patient with chronic hepatitis B and
decompensated cirrhosis.
Case description: In 2000, a 72-year-old man naı¨ve for
interferon and nucleos(t)ide analog therapy was HBsAg
positive and hepatitis B e antigen (HBeAg) negative,
with undetectable serum hepatitis B virus (HBV) DNA and
normal alanine aminotransferase (ALT) levels and with no
evidence of liver cirrhosis. In 2005, he had a diagnosis
of adenocarcinoma of the colon and underwent resection
and chemotherapy. In 2008 he was found HBsAg negative
and received FOLFIRI plus bevacizumab and subsequently
prednisone 25mg with tapering for 15 days because of a low
platelet count. In March 2009, the patient was HBsAg posi-
tive, HBe antibody positive, hepatitis delta virus/hepatitis C
virus negative, and had an HBVDNA level of 3.31×105 IU/mL
and an ALT level 8× the upper limit of normal (ULN).
Ultrasonography revealed evidence of cirrhosis and portal
hypertension with a Child Turcotte Pugh (CTP) score of 14
and a model for end-stage liver disease (MELD) score of 24.
In April 2009, telbivudine 600mg/day was initiated.
Serum HBVDNA became undetectable (<12 IU/mL) within
2 months and ALT 1.5×ULN. At 6 months of follow-up,
HBVDNA remained undetectable, his ALT level was 0.6×ULN,
and his total and conjugated bilirubin levels were 2.3 and
0.94mg/dL, respectively. Ultrasonography showed no evi-
dence of ascites and an improvement in liver status with a
reduction in CTP and MELD scores (7 and 13, respectively).
Telbivudine resulted in a rapid suppression of HBVDNA levels
and a marked improvement of an extremely severe clinical
condition. These ﬁndings suggest that telbivudine may be of
great beneﬁt even in patients with decompensated HBsAg-
positive liver cirrhosis.
PP-092 Clinical and epidemiological analysis of
384 patients diagnosed with acute hepatitis B
B.X. Chang1 *. 1Diagnosis and Therapy Center of
Non-Infectious Disease, 302 Hospital, China
Objective: To investigate the clinical and epidemiological
characteristics of acute hepatitis B (AHB) in recent years.
Methods: To analyze the clinical data of 384 patients of AHB
by using the software SPSS 13.0.
Results: This result indicated that the susceptible
population of AHB is the patients with the age changing
from 18 to 45. The main route of transmission remained
unknown. The main nationality was Han. The morbidity of
male was higher than that of female. The rate of recovery
and improvement was 98.9%.The incidence of liver failure
is 0.5%.Six months after onset, HBsAg in 97.1% cases and
HBVDNA in 98.5% cases changed into negative.
Conclusion: The age of morbidity and the route of
transmission have changed greatly. The rate of recovery
and improvement was higher. Only few of the AHB patients
converted to the chronic HB and severe hepatitis.
PP-093 The study of efﬁcacy of lamivudine in patients
with severe acute hepatitis B
J.-W. Yu1 *, L.-J. Sun1, Y.-H. Zhao1. 1Department of
Infectious Diseases, Second Afﬁliated Hospital, Harbin
Medical University, China
The aim of this study was to evaluate the efﬁcacy of
lamivudine in patients with severe acute hepatitis B.
Methods: Eighty patients with severe acute hepatitis B were
randomly divided into lamivudine and the control group.
The inﬂuential factors on the mortality were studied by Cox
proportional hazards model.
Results: The improvement in serum TBiL, INR and HBVDNA
levels of lamivudine group was signiﬁcantly greater than
that of control group. The mortality (7.5%, 3/40) of
lamivudine group was signiﬁcantly lower than that (25.0%,
10/40) of control group (P = 0.034). In multivariate Cox
proportional hazards analyses, age (P = 0.043), ratio of
total to direct bilirubin (P = 0.009), treatment method
(P = 0.006) and the decline of HBVDNA load during therapy
(P = 0.017) were independent predictors of mortality. The
HBsAg seroconversion rates (62.5%, 25/40) and HBeAg
seroconversion rates (63.6%, 21/33) of lamivudine group
were signiﬁcantly lower than those (85.0%, 34/40), (87.5%,
28/32) of control group (P = 0.022, 0.026).
Conclusions: Early treatment with lamivudine leads to
a greater decrease in HBVDNA level, better clinical
improvement and mortality improvement in patients with
severe acute hepatitis B, but with a lower seroconversion
rate. A rapid decline of HBVDNA load is a good predictor for
the treatment outcome.
PP-094 Inﬂuential factors of prognosis in lamivudine
treatment for patients with acute-on-chronic
hepatitis B liver failure
L.-J. Sun1, J.-W. Yu1 *, P. Kang1. 1Department of Infectious
Diseases, Second Afﬁliated Hospital, Harbin Medical
University, China
In this study, the efﬁcacy of lamivudine was investigated
in patients with ACLF. The effects of HBVDNA load and
its related factors on the prognosis were also further
explored.
Methods: 130 patients receiving lamivudine were selected
into the lamivudine treatment group with another 130
without lamivudine treatment studied as control. The
inﬂuential factors on the mortality were studied by Cox
proportional hazards model.
Results: The cumulative survival rates of patients in
lamivudine group were higher than those of the control
group (c2 = 9.50, P = 0.0021). The mortality of patients with
high virus load group (71/95, 74.7%) was higher than that of
those with low virus load group (15/29, 51.7%) (c2 = 5.536,
P = 0.019). In Cox proportional hazards model, for patients
with MELD score 20 30, treatment method (P = 0.002),
pretreatment HBVDNA load (P = 0.007) and decline of
HBVDNA load during therapy (P = 0.003) were independent
predictors; for those with MELD score above 30, MELD score
(P = 0.008) was the only independent predictor.
Conclusions: Lamivudine can signiﬁcantly decrease the
3-month mortality of patients with MELD score 20 30, and a
low pre-treatment viral load and rapid decline of HBVDNA
load are good predictors for the outcome of the treatment.
PP-095 Analysis of the efﬁcacy of treatment with
peginterferon-a-2a and ribavirin in patients
coinfected with hepatitis B virus and
hepatitis C virus
J.-W. Yu1 *, L.-J. Sun1. 1Department of Infectious Diseases,
Second Afﬁliated Hospital, Harbin Medical University,
China
Objective: To study efﬁcacy of combination therapy with
peginterferon a-2a and ribavirin in these patients.
Methods: The virological response rates of patients treated
with peginterferon a-2a and ribavirin between the HBV and
HCV coinfection group and the HCV monoinfection group
were compared.
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Results: The pEVR rate and ETVR rate (50.0%, 15/30; 90.0%,
27/30) of patients with genotype 1 in the coinfection
group were signiﬁcantly higher than those (16.0%, 4/25;
56.0%, 14/25) in the HCV monoinfection group (c2 = 6.971,
P= 0.008; c2 = 8.307, P= 0.004). The relapse rate (55.6%,
15/27) of patients with genotype 1 in the coinfection
group was signiﬁcantly higher than that (21.4%, 3/14) in
the HCV mono-infection group (c2 = 4.360, P= 0.037). The
SVR rate (40.0%, 12/30) of patients with genotype 1 in
the coinfection group was compared with that of the HCV
monoinfection group (44.0%, 11/25) (c2 = 0.090, P= 0.765).
The reactivation rate of HBVDNA (33.3%, 9/27) with HCV
SVR was signiﬁcantly higher than that of patients without
SVR (8.7%, 2/23) (c2 = 4.393, P= 0.036).
Conclusions: Compared with HCV-monoinfected patients,
pEVR, ETVR and relapse rates of patients with genotype 1
in the coinfection group were high, while they shared similar
SVR rates.
PP-096 Inhibition of the expression of CD147 by
MicroRNA and inﬂuence on the biological
activities of tumor in hepatic carcinoma cells
J. Tan1, M. Zhou2, A.-R. Hu1 *. 1Ningbo Infectious Diseases
Hospital, 2Ningbo University School of Medicine, China
Objective: Gene CD147 is overexpressed in many kinds
of carcinomas. It stimulats the surrounding ﬁbroblasts of
cancer cells to express matrix metalloproteinases and to
induce invasive and metastatic activities of tumors. Our
study was to test these biological activities after CD147 was
down-regulated by microRNA in hepatic carcinoma cells
HepG2 and discuss the inﬂuences of this treatment.
Methods: The plasmids pSilencer 4.1-CMV neo/CD147 siRNA
was reconstructed and then they were stablely transfected
into hepatic cancer cells HepG2. The expression of CD147
was detected by RT-PCR and Western blotting. Afterwards,
the method of MTT and Transwell were used to analyze
the proliferation and invasion of tumor respectively. The
experiment of nude mice was performed to observe the
tumor growth.
Results: The expression of CD147 mRNA and protein could be
inhibited by pSilencer 4.1-CMV neo/CD147 siRNA Sequence
1 and 2 (P < 0.05). Compared with the control group, the
proliferation of the two observed groups was reduced
46.14±2.62% vs 43.21±3.42%, 51.13±6.72% vs 51.15±6.65%
and 50.27±3.06% vs 49.21±2.13% (p < 0.05), respectively,
at 24h, 48h and 72h; the ability of invasion was decreased
52.01±1.42% and 53.16±5.01% (p < 0.05), respectively. After
cancer cells were transplanted into nude mice the tumor
volume of siRNA groups were smaller than the controls
(p < 0.01).
Conclusion: The expression of CD147 could be down-
regulated effectively by SiRNA plasmids and the invasion,
proliferation and the ability of forming tumor could
be inhibited evidently after this treatment in hepatic
carcinoma cells HepG2.
PP-097 Screening of hepatocyte proteins binding with
surface antigen middle protein of hepatitis B
virus (MHBs) by yeast two-hybrid system
Z.Q. Li1 *, S. Zhang1, Y. Zhu1, J. Cheng2. 1261 Hospital
of PLA, Beijing 100094, China, 2Institute of Infectious
Diseases, Beijing Ditan Hospital, Beijing 100011, China
Background: To screen and clone the genes of hepatocyte
protein interacting with MHBs. elucidate the biological
function of MHBs on pathogenesis of hepatitis.
Methods: PCR was used to amplify the gene of MHBs from
the plasmid A7 containing the whole fragment of adr subtype
of HBV, then PCR product was cloned into pGEM-T vector
and was evaluated by sequencing. The gene of MHBs was
cut by EcoRI and BamH I from pGEM-T vector then cloned
into yeast expression plasmid pGBKT7. The “bait” plasmid
pGBKT7-MHBs was transformed into yeast strain AH109
(a type) with yeast-two hybrid. The transformed yeast cells
were mated with yeast Y187 (a type) containing liver cDNA
library plasmid in 2×YPDA medium. Diploid yeast cells were
plated on SD/ Trp Leu His Ade and SD/ Trp Leu His Ade
containing X-a gal for screening twice. After extracting and
sequencing of plasmid from true positive blue colonies, we
isolated a cDNA clone encoding a novel protein designated
as MBP1 that directly interacted with MHBs. The results
were analyzed by bioinformatics.
Results: pGBKT7-MHBs yeast expressed vector was
successful constructed. Two colonies were sequenced, one
colone was ALDOB, another colone was new gene with
unknown function, which was named MBP1.
Conclusions: MHBs gene was successful cloned, The novel
protein MBP1 gene was screened and identiﬁed by yeast two-
hybrid, the results brought some new clues for studying the
biological functions of MBP1 and HBV induce carcinomatous
development mechanism.
PP-098 Screening of hepatocyte proteins binding with
C-terminally truncated surface antigen middle
protein of hepatitis B virus (MHBst167) by yeast
two-hybrid system
Z.Q. Li1 *, S. Zhang1, Y. Zhu1, J. Cheng2. 1261 Hospital
of PLA, Beijing 100094, China, 2Institute of Infectious
Diseases in Ditan hospital, Beijing 100011, China
Aim: The effect of MHBst167 protein is not clear. To screen
and identify the proteins which interact with hepatitis B
virus (HBV) MHBst167 protein in hepatocytes by yeast two-
hybrid system and to explore the effects of MHBst167 protein
in the development of hepatocellular carcinoma (HCC).
Methods: The MHBst167 gene was ampliﬁed by polymerase
chain reaction (PCR) method, and was cloned into pGEM-T
vector. After the target region was sequenced, and the
constructed yeast expression vector pGBKT7-MHBst167 was
transformed into yeast cells AH109 and the constructed
bait plasmid AH109 with pGBKT7-MHBst167 mate with
Y187 containing liver cDNA library plasmid by yeast-two
hybridization system 3. then were grown on quadruple
dropout medium and the second screen assayed for
x-a-gal activity was performed by the LacZ report gene.
Furthermore, after extracting and sequencing of plasmid
from blue colonies, and eliminate the false positive and the
true positive clones were selected by PCR and sequencing.
analysis by bioinformatics.
Results: The bait plasmid AH109 with pGBKT7-MHBst167was
successfully constructed and correctly expressed BD-
MHBst167 protein in yeast AH109. 66 clones grew in the
selective SC/-trp-leu-his-ade medium, and only 52 clones
passed through x-a-gal activity detection and segregation
analysis. Seven positive colonies that interacted with
MHBst167protein were obtained and sequenced; namely, two
Homo sapiens ADP-ribosylation factor 1, cDNA clone of Fetal
liver of Homo sapiens, Homo sapiens ALDOB gene, C3, Homo
sapiens BAC clone, somatomedin B.
Conclusion: Seven proteins is expressed that can interact
with MHBst167 in hepatocytes by yeast two-hybrid system.
These results brought some new clues for studying the
biological functions of MHBst167 protein.
